You Are Here    Home   News


Featured news from BHIVA

Change to recommended regimen for post-exposure prophylaxis (PEP)
by Admin, 2014-11-18 11:35

BHIVA responds to JCVI recommendation on HPV vaccination for MSM
by Admin, 2014-11-12 17:10

Council motion on HIV testing
by Admin, 2014-10-22 09:25

View more news from BHIVA

HIV-related news from NAM

AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection
by Liz Highleyman, 2014-11-21 09:20
AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both produced good sustained virological response rates for most people with HIV and hepatitis C virus (HCV) co-infection, according to studies presented at the American Association for the Study of Liver Diseases (AASLD)

Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients
by Liz Highleyman, 2014-11-19 18:50
  A 12-week oral combination of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high sustained virological response rates for people with difficult-to-treat HCV genotype 3 and other genotypes, according to phase 2 study findings presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston. Reducing treatment duration

HIV in the UK: 76% diagnosed, 90% on treatment, 90% undetectable
by Roger Pebody, 2014-11-19 08:50
The UK’s annual epidemiological report, released yesterday, shows that the country already provides HIV treatment to 90% of people attending clinical services and that 90% of those on treatment have an undetectable viral load. But the country has a long way to go in ensuring that people with HIV are aware of their HIV

Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients
by Liz Highleyman, 2014-11-17 06:50
People with chronic hepatitis B virus (HBV) infection are more likely to experience favourable treatment response, as indicated by hepatitis B surface antigen (HBsAg) loss, if they add pegylated interferon to tenofovir – although even then the cure rate falls short of 10%, researchers reported on Tuesday at the American Association for the Study of